Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients

Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients

CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) plays a crucial role in the stability of the programmed death-ligand 1 (PD-L1). However, there has been no previous study of CMTM6 in non-small cell lung cancer (NSCLC) and its association with PD-L1 has not been confirmed. The aim of this s...

Full description

Bibliographic Details
Main Authors:	Young Wha Koh, Jae-Ho Han, Seokjin Haam, Joonho Jung, Hyun Woo Lee
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-10-01
Series:	OncoImmunology
Subjects:	non-small cell lung cancer cmtm6 pd-l1 biomarker
Online Access:	http://dx.doi.org/10.1080/2162402X.2019.1629261

Similar Items

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
by: Hiroto Takeuchi, et al.
Published: (2020-06-01)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
by: Xin Li, et al.
Published: (2020-08-01)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
by: Chao Zhang, et al.
Published: (2021-01-01)

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
by: Zhang S, et al.
Published: (2020-06-01)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
by: Sandra Martinez-Morilla, et al.
Published: (2021-01-01)

HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis
by: Young Wha Koh, et al.
Published: (2020-05-01)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
by: Song Xin, et al.
Published: (2021-01-01)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
by: Malina Xiao, et al.
Published: (2021-03-01)

CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells
by: Xiaoting Huang, et al.
Published: (2021-03-01)

Overexpression of CMTM7 inhibits cell growth and migration in liver cancer
by: Zi‐Ming Huang, et al.
Published: (2019-06-01)

MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4
by: Hongxia Zhang, et al.
Published: (2015-10-01)

CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
by: Wanqiong Yuan, et al.
Published: (2021-09-01)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
by: Yanbin Zhao, et al.
Published: (2021-01-01)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
by: Zhi Chen, et al.
Published: (2021-01-01)

CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value
by: Jie Wu, et al.
Published: (2020-08-01)

CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling
by: Gang Xu, et al.
Published: (2017-11-01)

Interaction of the CMTM7 rs347134 Polymorphism with Dietary Patterns and the Risk of Obesity in Han Chinese Male Children
by: Qi Zhu, et al.
Published: (2020-02-01)

CMTM3 suppresses bone formation and osteogenic differentiation of mesenchymal stem cells through inhibiting Erk1/2 and RUNX2 pathways
by: Dongwei Fan, et al.
Published: (2021-11-01)

Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer
by: Guanxuan CHEN, et al.
Published: (2018-09-01)

CMTM7 as a novel molecule of ATG14L-Beclin1-VPS34 complex enhances autophagy by Rab5 to regulate tumorigenicity
by: Baocai Liu, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
by: Keisuke Onoi, et al.
Published: (2020-05-01)

miR-149-5p Regulates Goat Hair Follicle Stem Cell Proliferation and Apoptosis by Targeting the CMTM3/AR Axis During Superior-Quality Brush Hair Formation
by: Jian Wang, et al.
Published: (2020-11-01)

Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis
by: Chong Lu, et al.
Published: (2021-07-01)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
by: Meng‐Meng Teng, et al.
Published: (2021-09-01)

PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer
by: Savić Ivana, et al.
Published: (2018-01-01)

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
by: Li B, et al.
Published: (2018-06-01)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
by: Xiaoyang Zhai, et al.
Published: (2020-09-01)

Tumor Nonimmune-Microenvironment-Related Gene Expression Signature Predicts Brain Metastasis in Lung Adenocarcinoma Patients after Surgery: A Machine Learning Approach Using Gene Expression Profiling
by: Seokjin Haam, et al.
Published: (2021-09-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
by: Xiang Li, et al.
Published: (2021-01-01)

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
by: Yanhui Chen, et al.
Published: (2019-05-01)

Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
by: Shumin Yuan, et al.
Published: (2020-11-01)

Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis
by: SHEN Shijun, et al.
Published: (2021-03-01)

Serum immune modulators during the first cycle of anti‐PD‐1 antibody therapy in non‐small cell lung cancer: Perforin as a biomarker
by: Takayo Ota, et al.
Published: (2020-11-01)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
by: Francesco Facchinetti, et al.
Published: (2020-09-01)

Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma
by: Fan L, et al.
Published: (2020-10-01)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
by: Ana Bocanegra, et al.
Published: (2019-04-01)

The frequency of high PD-L1 expression is low in lung adenocarcinoma patients from Northeast Brazil
by: Antonio V. Alves da Silva, et al.
Published: (2019-02-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
by: Jorge García-González, et al.
Published: (2020-07-01)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_u01dk7magmh1r504hsujaqvs9t